Press / media

As an institution of application-oriented research, the Fraunhofer Institute for Cell Therapy and Immunology IZI attaches great importance to informing customers and the public.

Latest press releases


Rapid diagnostic device for trachoma eye infection delivers first promising result

A molecular biological, chip-based rapid test for the diagnosis of the eye infection trachoma developed at the Fraunhofer Institute for Cell Therapy and Immunology IZI has proven promising in first studies. The results of the study carried out together with the London School of Hygiene & Tropical Medicine and the Kilimanjaro Christian Medical Centre, Tanzania, have now been published in the journal "Parasites & Vectors". The development of the DjinniChip was supported by the ClearTrachoma project of the non-profit organization Task Force for Global Health in a program of the Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD).
Read more


Fraunhofer IZI presents new technologies and services for the healthcare industry at the Fraunhofer Solution Days

The first Fraunhofer Solution Days will take place digitally from October 26 to 29, 2020. The online event of the Fraunhofer-Gesellschaft is dedicated to the four topics health, digital economy, plant and mechanical engineering and mobility. The Fraunhofer Institute for Cell Therapy and Immunology IZI is participating with various exhibits and lectures, particularly in the field of health.
Read more


Viromers suitable as carrier systems for gene-based treatment of inflammatory diseases

A project team from the Fraunhofer Institute for Cell Therapy and Immunology IZI and Lipocalyx GmbH (today: BioNTech Delivery Technologies GmbH) has now been able to prove that viromers are a suitable carrier material for messenger RNA (mRNA). In studies, the viromers developed by Lipocalyx proved to be a suitable therapeutic option for mRNA delivery in the treatment of a model for inflammatory diseases. The results were published in "Scientific Reports", an open access journal of the Nature Publishing Group.
Read more


Fraunhofer IZI cooperates with Nomad Bioscience to develop novel anti-bacterial and anti-viral medications

The Fraunhofer Institute for Cell Therapy and Immunology (IZI) will, in future, cooperate with Nomad Bioscience GmbH in developing anti-bacterial and anti-viral medications. The Fraunhofer IZI Department of Drug Design and Target Validation based in Halle (Saale) and the company with headquarters in Munich concluded a relevant research and development agreement in July 2020.
Read more

Archive press releases

RSS Newsfeed

Get the latest news about the Fraunhofer IZI. Through our RSS-feed you have the opportunity to follow all our press releases and receive them right when they are published.

Social media


Media library